FDA committee recommends authorizing Novavax to be fourth COVID-19 vaccine approved in the U.S.
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
- Mifepristone: A Safe and Effective Abortion Option Amidst Controversy
- Asbestos Detected in Buildings Damaged in Ukraine: Analyzed by Japanese Company
FDA committee recommends authorizing Novavax to be fourth COVID-19 vaccine approved in the U.S.
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
FDA committee recommends authorizing Novavax to be fourth COVID-19 vaccine approved in the U.S.
On June 07, a committee of scientists and physicians advising the U.S. Food and Drug Administration (FDA) voted to recommend that the FDA authorize the Novavax COVID-19 vaccine for adults 18 and older, CNET reported .
If the FDA accepts the committee’s recommendation and authorizes Novavax, two doses of the vaccine given three weeks apart, it would be the fourth COVID-19 vaccine to win emergency use authorization in the United States.
It would also make Novavax the first protein-based COVID-19 vaccine, a more traditional technology used for vaccines such as shingles. Since it’s a more established type of vaccine, it’s hoped Novavax will fill an unmet need for those who are hesitant to receive an mRNA vaccine made by Pfizer and Moderna. Use of Johnson & Johnson’s third licensed vaccine has been limited.
This protein-based vaccine is also easier to store and distribute than other vaccines. In a clinical trial, the Novavax vaccine was 90 percent effective against symptomatic COVID-19 (primarily Alpha) variants, but more research is needed to determine its response to Omicron.
Novavax was an early beneficiary of the Operation Warp Speed program, but the company ran into manufacturing issues that the FDA needed to confirm before authorizing its vaccine, The New York Times reported. Vaccines then typically go through the same voting and recommendation process by the Centers for Disease Control and Prevention (CDC) and its advisory committees before they are made available to the public.
Novavax filed an emergency use authorization application with the FDA in January, and it has been authorized for use in other countries, including Canada.
COVID-19 cases in the U.S. have risen sharply in recent weeks but have begun to level off, especially on the East Coast and Midwest. Experts expect another surge in cases in the fall or winter, and an FDA committee is scheduled to meet later this month to discuss new formulations of a COVID-19 vaccine that may better target Omicron and its subvariants.
About 83 percent of the U.S. population has received at least one dose of the COVID-19 vaccine, according to the CDC.
FDA committee recommends authorizing Novavax to be fourth COVID-19 vaccine approved in the U.S.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
